Drugs / C3F8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01835067 | Sep 2014 → Nov 2019 | retinal vascular disorder, wet macular degeneration | King's College Hospital NHS Trust | Completed | Mixed |
| Phase 41 trial | ||||||
| Phase 4 | NCT04527848 | May 2016 → Jul 2020 | macular holes | Federal University of Pernambuco | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT00673296 Background | Jan 2007 → Apr 2008 | diabetic retinopathy | National Taiwan University Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C3F8 | “receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting” NCT00673296 ↗ |
| Known as | perfluoropropane | “utilizing a small amount of undiluted C3F8 (perfluoropropane) versus a large amount of diluted C3F8 versus a small amount of undiluted SF6 (sulfur hexafluoride)” NCT04527848 ↗ |
| Modality | Other / unclassified | “intraocular gas injection” NCT04527848 ↗ |
| Route | Intravitreal | “receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting” NCT00673296 ↗ |